true0001326110P3Y--10-01P1YP1YP7Y2030-12-31P3YP5YP2YP1Y2017-01-31P5YP1YThe contingent consideration obligations were related to the acquisitions of VivaBioCell, S.p.A., or VivaBioCell, and Receptome, LLC, or Receptome. The contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on significant inputs not observable in the market (a Level 3 measurement within the fair value hierarchy) and are reviewed periodically by management. These inputs include the estimated probabilities and timing of achieving specified development and sales milestones, as well as the discount rate used to determine the present value of these milestones. Contingent considerations may change significantly as development progresses and additional data are obtained. Significant changes that would increase or decrease the probabilities or timing of achieving the development and sales milestones would result in a corresponding increase or decrease in the fair value of the contingent consideration obligations, which would be recognized on the combined consolidated statements of operations. During the year ended December 31, 2019, a contingent milestone had been reached which resulted in the recognition of a $0.8 million contingent consideration fair value adjustment which was included in accrued expenses and other current liabilities on the combined consolidated balance sheets. See Note 8 Commitments and Contingencies for additional information. 0001326110 2021-03-05 2021-03-05 0001326110 2020-12-31 0001326110 2019-12-31 0001326110 2020-01-01 2020-12-31 0001326110 2019-01-01 2019-12-31 0001326110 2015-11-30 0001326110 2021-03-09 0001326110 2019-07-01 2019-07-31 0001326110 2019-04-30 0001326110 2015-11-01 2020-12-31 0001326110 2019-08-09 2019-08-09 0001326110 2019-01-01 2019-03-31 0001326110 2016-09-30 0001326110 2018-12-31 0001326110 ibrx:NantcellCommonStockMember ibrx:MergerWithNantcellMember 2020-12-31 0001326110 ibrx:GlobeimmuneMember 2020-12-31 0001326110 ibrx:GlobeimmuneMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-12-31 0001326110 us-gaap:IntellectualPropertyMember 2020-12-31 0001326110 ibrx:RiptideBioscienceMember ibrx:ClinicalRegulatoryAndCommercialMilestonesMember 2020-12-31 0001326110 ibrx:RiptideBioscienceMember ibrx:ClinicalRegulatoryAndCommercialMilestonesMember srt:MaximumMember 2020-12-31 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember 2020-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2020-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2020-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2020-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2020-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 ibrx:DueFromRelatedPartyNantbioMember 2020-12-31 0001326110 ibrx:DueFromRelatedPartyNantomicsMember 2020-12-31 0001326110 ibrx:DueFromRelatedPartiesVariousMember 2020-12-31 0001326110 ibrx:DueToRelatedPartyNantworksMember 2020-12-31 0001326110 ibrx:DueToRelatedPartyDuleyRoadMember 2020-12-31 0001326110 ibrx:DueToRelatedPartyNantbioMember 2020-12-31 0001326110 ibrx:DueToRelatedPartyNantpharmaMember 2020-12-31 0001326110 ibrx:DueToRelatedPartyImmunooncologyClinicMember 2020-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantcapitalMember 2020-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantmobileMember 2020-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantworksMember 2020-12-31 0001326110 ibrx:RelatedPartyNotesPayableNcscMember 2020-12-31 0001326110 ibrx:ReceptomeMember 2020-12-31 0001326110 ibrx:AltarBioScienceCorporationMember ibrx:BeforeThirtyFirstDecemberTwoThousandAndTwentyTwoMember ibrx:ApprovalOfBilogicsLicenseApplicationMember 2020-12-31 0001326110 ibrx:AltarBioScienceCorporationMember ibrx:BeforeThirtyFirstDecemberTwoThousandAndTwentySixMember ibrx:SalesBasedMilestoneMember 2020-12-31 0001326110 ibrx:AltarBioScienceCorporationMember 2020-12-31 0001326110 ibrx:RelatingToTheManufacturingOfCgmpBatchesMember 2020-12-31 0001326110 ibrx:BioreactorsMember ibrx:NantbioIncMember 2020-12-31 0001326110 ibrx:SupplyAgreementMember ibrx:NantbioIncMember 2020-12-31 0001326110 ibrx:DueToRelatedPartiesMember 2020-12-31 0001326110 ibrx:AltorBioscienceManufacturingCompanyLLCMember ibrx:GrayAdamRWaldmansturmWaldmanAndDoughlasMember ibrx:ClaimToTheDissentingShareholdersMember 2020-12-31 0001326110 ibrx:SharedServicesAgreementMember ibrx:NantbioIncMember 2020-12-31 0001326110 ibrx:DueToRelatedPartiesMember ibrx:DuleyRoadLlcMember 2020-12-31 0001326110 ibrx:DuleyRoadLlcMember 2020-12-31 0001326110 us-gaap:OtherAssetsMember 2020-12-31 0001326110 ibrx:NantPharmaMember 2020-12-31 0001326110 ibrx:NantworksMember 2020-12-31 0001326110 ibrx:NantcapitalMember ibrx:DueToRelatedPartiesMember 2020-12-31 0001326110 ibrx:NantmobileMember 2020-12-31 0001326110 ibrx:NcscMember 2020-12-31 0001326110 ibrx:NantcapitalMember 2020-12-31 0001326110 ibrx:NantcapitalMember ibrx:SixPercentPromissoryNotesMember 2020-12-31 0001326110 ibrx:MarketableSecuritiesMember 2020-12-31 0001326110 ibrx:NantOmicsMember 2020-12-31 0001326110 ibrx:AccruedExpensesAndOtherLiabilitiesMember ibrx:IosbioLtdExclusiveLicenseAgreementMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2020-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001326110 ibrx:OutstandingRelatedPartyWarrantsMember 2020-12-31 0001326110 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001326110 us-gaap:EquipmentMember 2020-12-31 0001326110 us-gaap:BuildingMember 2020-12-31 0001326110 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001326110 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001326110 us-gaap:ConstructionInProgressMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeOneMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTwoMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeThreeMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeFourMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeFiveMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeSixMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeSevenMember 2020-12-31 0001326110 srt:MinimumMember us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeEightMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeEightMember srt:MaximumMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeNineMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTenMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeElevenMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTwelveMember 2020-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001326110 us-gaap:DebtSecuritiesMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeEightMember 2020-12-31 0001326110 ibrx:CurrentAssetsMember 2020-12-31 0001326110 ibrx:ForeignBondsMember ibrx:NoncurrentAssetsMember 2020-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:MutualFundMember 2020-12-31 0001326110 ibrx:NoncurrentAssetsMember 2020-12-31 0001326110 us-gaap:DomesticCountryMember 2020-12-31 0001326110 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001326110 us-gaap:ForeignCountryMember 2020-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember 2020-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001326110 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2020-12-31 0001326110 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2020-12-31 0001326110 ibrx:TwoThousandFifteenEquityIncentivePlanMember 2020-12-31 0001326110 ibrx:CytrxCorporationexclusiveLicenseAgreementMember 2020-12-31 0001326110 ibrx:CancerTherapeuticsLaboratoriesIncexclusiveLicenseAgreementMember 2020-12-31 0001326110 ibrx:EmployeeRestrictedStockUnitMember 2020-12-31 0001326110 ibrx:NonEmployeeRestrictedStockUnitMember 2020-12-31 0001326110 srt:MaximumMember 2020-12-31 0001326110 srt:MinimumMember 2020-12-31 0001326110 ibrx:ImmunoOncologyClinicIncMember stpr:CA 2020-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:SharedServicesAgreementMember ibrx:ReimbursementsMember 2020-12-31 0001326110 ibrx:NantHealthLabsIncMember 2020-12-31 0001326110 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001326110 ibrx:NashLLCMember 2020-01-01 2020-12-31 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:ExecutiveChairmanAndPrincipalStockholderMember 2020-01-01 2020-12-31 0001326110 ibrx:MergerWithNantcellMember 2020-01-01 2020-12-31 0001326110 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001326110 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001326110 us-gaap:StockholdersEquityTotalMember 2020-01-01 2020-12-31 0001326110 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001326110 country:US 2020-01-01 2020-12-31 0001326110 srt:EuropeMember 2020-01-01 2020-12-31 0001326110 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ibrx:GlobeimmuneMember 2020-01-01 2020-12-31 0001326110 ibrx:SubleaseMiramarFloridaMember 2020-01-01 2020-12-31 0001326110 us-gaap:IntellectualPropertyMember 2020-01-01 2020-12-31 0001326110 ibrx:SharedServicesAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:SharedServicesAgreementMember ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:ReimbursementsMember 2020-01-01 2020-12-31 0001326110 ibrx:NationalCancerInstituteOfTheNationalInstitutesOfHealthMember ibrx:CooperativeResearchAndDevelopmentAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:CooperativeResearchAndDevelopmentAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:AmendedCooperativeResearchAndDevelopmentAgreementMember ibrx:NationalCancerInstituteOfTheNationalInstitutesOfHealthMember 2020-01-01 2020-12-31 0001326110 ibrx:CancerTherapeuticsLaboratoriesIncexclusiveLicenseAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:AltorAcquisitionMember ibrx:NantHealthLabsIncMember 2020-01-01 2020-12-31 0001326110 ibrx:NantHealthLabsIncMember 2020-01-01 2020-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember 2020-01-01 2020-12-31 0001326110 ibrx:NantBioScienceMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-01-01 2020-12-31 0001326110 ibrx:ImmunoOncologyClinicIncMember stpr:CA 2020-01-01 2020-12-31 0001326110 ibrx:CancerTherapeuticsLaboratoriesIncexclusiveLicenseAgreementMember ibrx:ClinicalAndRegulatoryMilestonesMember 2020-01-01 2020-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember 2020-01-01 2020-12-31 0001326110 ibrx:AltarBioScienceCorporationMember 2020-01-01 2020-12-31 0001326110 ibrx:GasMixersAndConsumablesMember ibrx:NantbioIncMember 2020-01-01 2020-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember ibrx:DuleyRoadLlcMember 2020-01-01 2020-12-31 0001326110 ibrx:TwoLeasesMember us-gaap:ResearchAndDevelopmentExpenseMember ibrx:DuleyRoadLlcMember 2020-01-01 2020-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember ibrx:SixZeroFiveDougStLlcMember 2020-01-01 2020-12-31 0001326110 ibrx:LaboratoryRelocationMember 2020-01-01 2020-12-31 0001326110 ibrx:LaboratoryRelocationMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0001326110 ibrx:InterestAndInvestmentIncomeNetMember 2020-01-01 2020-12-31 0001326110 ibrx:FourHundredOneKPlanMember 2020-01-01 2020-12-31 0001326110 ibrx:ITEquipmentMember 2020-01-01 2020-12-31 0001326110 us-gaap:BuildingMember 2020-01-01 2020-12-31 0001326110 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001326110 ibrx:LaboratoryEquipmentMember srt:MinimumMember 2020-01-01 2020-12-31 0001326110 ibrx:LaboratoryEquipmentMember srt:MaximumMember 2020-01-01 2020-12-31 0001326110 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001326110 srt:MaximumMember 2020-01-01 2020-12-31 0001326110 srt:MinimumMember 2020-01-01 2020-12-31 0001326110 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001326110 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001326110 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001326110 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001326110 ibrx:EmployeeAndNonEmployeeRestrictedStockUnitMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeSixMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeFiveMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeFourMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeThreeMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTwoMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeOneMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTwelveMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeElevenMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeEightMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeSevenMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeNineMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:ExercisePriceRangeTenMember 2020-01-01 2020-12-31 0001326110 ibrx:OtherIncomeAndExpenseNetMember 2020-01-01 2020-12-31 0001326110 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001326110 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001326110 ibrx:TaxYear2021AndThereafterMember 2020-01-01 2020-12-31 0001326110 us-gaap:TaxYear2020Member 2020-01-01 2020-12-31 0001326110 country:KR 2020-01-01 2020-12-31 0001326110 ibrx:NoncurrentAssetsMember ibrx:ForeignBondsMember 2020-01-01 2020-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001326110 us-gaap:ResearchMember us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001326110 us-gaap:ResearchMember us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001326110 ibrx:TwoThousandFifteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001326110 ibrx:EmployeeRestrictedStockUnitMember 2020-01-01 2020-12-31 0001326110 ibrx:NonEmployeeRestrictedStockUnitMember 2020-01-01 2020-12-31 0001326110 us-gaap:DomesticCountryMember srt:MinimumMember 2020-01-01 2020-12-31 0001326110 us-gaap:DomesticCountryMember srt:MaximumMember 2020-01-01 2020-12-31 0001326110 country:KR srt:MinimumMember 2020-01-01 2020-12-31 0001326110 country:KR srt:MaximumMember 2020-01-01 2020-12-31 0001326110 us-gaap:StateAndLocalJurisdictionMember srt:MinimumMember 2020-01-01 2020-12-31 0001326110 us-gaap:StateAndLocalJurisdictionMember srt:MaximumMember 2020-01-01 2020-12-31 0001326110 country:IT srt:MinimumMember 2020-01-01 2020-12-31 0001326110 country:IT srt:MaximumMember 2020-01-01 2020-12-31 0001326110 ibrx:PrecigenLicenseAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:GlobeimmuneExclusiveLicenseAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:CytrxCorporationexclusiveLicenseAgreementMember 2020-01-01 2020-12-31 0001326110 ibrx:CytrxCorporationexclusiveLicenseAgreementMember ibrx:RegulatoryApprovalsAndCommercialMilestonesMember 2020-01-01 2020-12-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2020-01-01 2020-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001326110 ibrx:Etbx021Member ibrx:NantBioScienceMember 2020-01-01 2020-12-31 0001326110 ibrx:NashLLCMember ibrx:ElSegundoCaliforniaMember 2021-02-28 0001326110 ibrx:NashLLCMember 2021-02-28 0001326110 ibrx:PromissoryNoteMember 2021-02-28 0001326110 ibrx:NashLLCMember 2021-02-28 2021-02-28 0001326110 ibrx:NantcellIncMember 2021-03-09 0001326110 ibrx:NantcellCommonStockMember 2021-03-09 0001326110 ibrx:CompanyCommonStockMember 2021-03-09 0001326110 ibrx:NantcellIncMember 2021-03-09 2021-03-09 0001326110 ibrx:NantcellCommonStockMember 2021-03-09 2021-03-09 0001326110 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001326110 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001326110 us-gaap:StockholdersEquityTotalMember 2019-01-01 2019-12-31 0001326110 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001326110 country:US 2019-01-01 2019-12-31 0001326110 srt:EuropeMember 2019-01-01 2019-12-31 0001326110 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ibrx:GlobeimmuneMember 2019-01-01 2019-12-31 0001326110 ibrx:CaMember ibrx:FirstAndSecondLeaseMember 2019-01-01 2019-12-31 0001326110 us-gaap:IntellectualPropertyMember 2019-01-01 2019-12-31 0001326110 ibrx:SharedServicesAgreementMember 2019-01-01 2019-12-31 0001326110 ibrx:SharedServicesAgreementMember ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:ReimbursementsMember 2019-01-01 2019-12-31 0001326110 ibrx:AmendedCooperativeResearchAndDevelopmentAgreementMember ibrx:NationalCancerInstituteOfTheNationalInstitutesOfHealthMember 2019-01-01 2019-12-31 0001326110 ibrx:AltorAcquisitionMember ibrx:NantHealthLabsIncMember 2019-01-01 2019-12-31 0001326110 ibrx:NantHealthLabsIncMember 2019-01-01 2019-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember 2019-01-01 2019-12-31 0001326110 ibrx:NantBioScienceMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-01-01 2019-12-31 0001326110 ibrx:ImmunoOncologyClinicIncMember stpr:CA 2019-01-01 2019-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember 2019-01-01 2019-12-31 0001326110 ibrx:GasMixersAndConsumablesMember ibrx:NantbioIncMember 2019-01-01 2019-12-31 0001326110 ibrx:PrecisionBiologicsMember ibrx:InvestmentsInSeriesAPreferredStockMember 2019-01-01 2019-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember ibrx:DuleyRoadLlcMember 2019-01-01 2019-12-31 0001326110 ibrx:TwoLeasesMember us-gaap:ResearchAndDevelopmentExpenseMember ibrx:DuleyRoadLlcMember 2019-01-01 2019-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember ibrx:SixZeroFiveDougStLlcMember 2019-01-01 2019-12-31 0001326110 ibrx:InterestAndInvestmentIncomeNetMember 2019-01-01 2019-12-31 0001326110 ibrx:FourHundredOneKPlanMember 2019-01-01 2019-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001326110 srt:MaximumMember 2019-01-01 2019-12-31 0001326110 srt:MinimumMember 2019-01-01 2019-12-31 0001326110 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001326110 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001326110 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001326110 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001326110 ibrx:EmployeeAndNonEmployeeRestrictedStockUnitMember 2019-01-01 2019-12-31 0001326110 us-gaap:CommonStockMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 us-gaap:AccountingStandardsUpdate201409Member us-gaap:StockholdersEquityTotalMember 2019-01-01 2019-12-31 0001326110 us-gaap:NoncontrollingInterestMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001326110 ibrx:NationalCancerInstituteOfTheNationalInstitutesOfHealthMember ibrx:CooperativeResearchAndDevelopmentAgreementMember 2019-01-01 2019-12-31 0001326110 ibrx:PrecigenLicenseAgreementMember 2019-01-01 2019-12-31 0001326110 ibrx:DirectorsAndOfficersInsurancePolicyMember 2019-01-01 2019-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001326110 ibrx:Etbx021Member ibrx:NantBioScienceMember 2019-01-01 2019-12-31 0001326110 ibrx:GlobeimmuneMember 2019-12-31 0001326110 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ibrx:GlobeimmuneMember 2019-12-31 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember 2019-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2019-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2019-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember 2019-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:CurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember ibrx:NoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001326110 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001326110 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001326110 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001326110 ibrx:DueFromRelatedPartyNantbioMember 2019-12-31 0001326110 ibrx:DueFromRelatedPartyNantomicsMember 2019-12-31 0001326110 ibrx:DueFromRelatedPartiesVariousMember 2019-12-31 0001326110 ibrx:DueToRelatedPartyNantworksMember 2019-12-31 0001326110 ibrx:DueToRelatedPartyDuleyRoadMember 2019-12-31 0001326110 ibrx:DueToRelatedPartyNantbioMember 2019-12-31 0001326110 ibrx:DueToRelatedPartyNantpharmaMember 2019-12-31 0001326110 ibrx:DueToRelatedPartyImmunooncologyClinicMember 2019-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantcapitalMember 2019-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantmobileMember 2019-12-31 0001326110 ibrx:RelatedPartyNotesPayableNantworksMember 2019-12-31 0001326110 ibrx:RelatedPartyNotesPayableNcscMember 2019-12-31 0001326110 ibrx:ContingentMilestoneMember ibrx:AccruedExpensesAndOtherCurrentLiabilitiesMember 2019-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember ibrx:ClinicalMilestoneMember 2019-12-31 0001326110 ibrx:BioreactorsMember ibrx:NantbioIncMember 2019-12-31 0001326110 ibrx:SupplyAgreementMember ibrx:NantbioIncMember 2019-12-31 0001326110 ibrx:DueToRelatedPartiesMember 2019-12-31 0001326110 ibrx:PrecisionBiologicsMember ibrx:InvestmentsInSeriesAPreferredStockMember 2019-12-31 0001326110 ibrx:AltorBioscienceManufacturingCompanyLLCMember ibrx:GrayAdamRWaldmansturmWaldmanAndDoughlasMember ibrx:ClaimToTheDissentingShareholdersMember 2019-12-31 0001326110 ibrx:SharedServicesAgreementMember ibrx:NantbioIncMember 2019-12-31 0001326110 ibrx:DueToRelatedPartiesMember ibrx:DuleyRoadLlcMember 2019-12-31 0001326110 ibrx:DuleyRoadLlcMember 2019-12-31 0001326110 us-gaap:OtherAssetsMember 2019-12-31 0001326110 ibrx:NantmobileMember 2019-12-31 0001326110 ibrx:NantPharmaMember 2019-12-31 0001326110 ibrx:NantcapitalMember 2019-12-31 0001326110 ibrx:NantcapitalMember ibrx:DueToRelatedPartiesMember 2019-12-31 0001326110 ibrx:NantworksMember 2019-12-31 0001326110 ibrx:NcscMember 2019-12-31 0001326110 ibrx:MarketableSecuritiesMember 2019-12-31 0001326110 ibrx:NantOmicsMember 2019-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2019-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001326110 ibrx:OutstandingRelatedPartyWarrantsMember 2019-12-31 0001326110 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001326110 us-gaap:EquipmentMember 2019-12-31 0001326110 us-gaap:BuildingMember 2019-12-31 0001326110 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0001326110 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001326110 us-gaap:ConstructionInProgressMember 2019-12-31 0001326110 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001326110 us-gaap:AgencySecuritiesMember 2019-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001326110 ibrx:CurrentAssetsMember ibrx:ForeignBondsMember 2019-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:AgencySecuritiesMember 2019-12-31 0001326110 ibrx:CurrentAssetsMember us-gaap:MutualFundMember 2019-12-31 0001326110 ibrx:CurrentAssetsMember 2019-12-31 0001326110 ibrx:NoncurrentAssetsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001326110 ibrx:NoncurrentAssetsMember ibrx:ForeignBondsMember 2019-12-31 0001326110 ibrx:NoncurrentAssetsMember 2019-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember 2019-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001326110 ibrx:ContingentConsiderationObligationMember us-gaap:FairValueMeasurementsNonrecurringMember ibrx:LiabilitiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001326110 ibrx:CytrxCorporationexclusiveLicenseAgreementMember 2019-12-31 0001326110 ibrx:CancerTherapeuticsLaboratoriesIncexclusiveLicenseAgreementMember 2019-12-31 0001326110 ibrx:ImmunoOncologyClinicIncMember stpr:CA 2019-12-31 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:SharedServicesAgreementMember ibrx:ReimbursementsMember 2019-12-31 0001326110 ibrx:NantHealthLabsIncMember 2019-12-31 0001326110 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0001326110 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001326110 ibrx:NantPharmaMember 2018-01-01 2018-12-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2014-03-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFourteenEquityIncentivePlanMember us-gaap:CommonStockMember srt:MaximumMember 2014-01-01 2014-03-31 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFifteenEquityIncentivePlanMember 2019-01-01 2019-06-30 0001326110 ibrx:NantcapitalMember 2019-06-01 2019-06-30 0001326110 us-gaap:EmployeeStockOptionMember ibrx:TwoThousandFifteenEquityIncentivePlanMember 2019-06-01 2019-06-30 0001326110 us-gaap:CommonStockMember ibrx:KuwaitInvestmentAuthorityMember 2019-03-11 0001326110 us-gaap:CommonStockMember ibrx:KuwaitInvestmentAuthorityMember 2019-03-11 2019-03-11 0001326110 us-gaap:CommonStockMember ibrx:StockTransferAgreementMember 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:ExecutiveChairmanMember 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:NantworksMember 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:NantworksMember 2019-09-26 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:WarrantsMember 2019-09-26 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:ExecutiveChairmanMember 2019-09-26 2019-09-26 0001326110 us-gaap:CommonStockMember ibrx:StockTransferAgreementMember 2019-09-26 2019-09-26 0001326110 ibrx:AltorAcquisitionMember ibrx:UnvestedWarrantsMember 2019-09-26 2019-09-26 0001326110 ibrx:ExecutiveChairmanMember 2019-06-28 0001326110 ibrx:CalcapMember 2019-06-28 0001326110 ibrx:CalcapMember 2019-06-28 2019-06-28 0001326110 ibrx:ExecutiveChairmanMember 2019-06-28 2019-06-28 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember 2015-11-30 0001326110 ibrx:UnderwrittenPublicOfferingMember 2020-06-28 2020-06-29 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:PublicMember 2020-06-28 2020-06-29 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:SharesSoldToPublicUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalSharesMember 2020-06-28 2020-06-29 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:PublicMember 2020-06-29 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:ExecutiveChairmanAndPrincipalStockholderMember 2020-06-29 0001326110 ibrx:UnderwrittenPublicOfferingMember ibrx:SharesSoldToPublicUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalSharesMember 2020-06-29 0001326110 ibrx:CalcapMember 2019-01-01 0001326110 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001326110 us-gaap:AccountingStandardsUpdate201602Member ibrx:DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member 2019-01-01 0001326110 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-01-01 0001326110 ibrx:NantbioIncMember 2018-08-01 2018-08-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2018-08-01 2018-08-31 0001326110 ibrx:NantBioScienceMember 2018-08-01 2018-08-31 0001326110 ibrx:NantcancerstemcellLlcMember ibrx:NantbioIncMember 2018-08-01 2018-08-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2016-06-01 2016-06-30 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2016-06-30 0001326110 ibrx:NantBioScienceMember 2016-03-01 2016-03-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2016-03-01 2016-03-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2016-03-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2019-07-01 2019-09-30 0001326110 ibrx:DougStLLCMember 2019-08-31 0001326110 ibrx:CommitmentWoburnMassachusettsMember srt:ScenarioForecastMember 2021-06-01 2021-06-01 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2021-06-01 2021-06-01 0001326110 ibrx:SixZeroFiveDougStLlcMember 2016-09-30 0001326110 ibrx:SixZeroFiveDougStLlcMember 2016-09-01 2016-09-30 0001326110 ibrx:DougStLLCMember 2016-09-01 2016-09-30 0001326110 ibrx:CommitmentWoburnMassachusettsMember 2016-09-01 2016-09-30 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember 2015-11-01 2015-11-30 0001326110 ibrx:AmendmentToExtendLeaseTermMember ibrx:NantWorksLimitedLiabilityCompanyMember 2020-09-01 2020-09-30 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember 2020-09-01 2020-09-30 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:AmendmentToExtendLeaseTermMember 2021-01-01 2021-01-01 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember srt:ScenarioForecastMember ibrx:AmendmentToExtendLeaseTermMember 2022-01-01 2022-01-01 0001326110 ibrx:PrecisionBiologicsMember 2019-06-30 0001326110 ibrx:NantcapitalMember 2019-06-30 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember 2018-06-30 2018-06-30 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember 2018-09-30 2018-09-30 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember 2018-06-30 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember 2018-09-30 0001326110 ibrx:NantcapitalMember 2019-05-31 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember us-gaap:CommonStockMember 2019-05-31 0001326110 ibrx:CaMember ibrx:FirstLeaseForTheFirstFloorOfTheBuildingMember 2019-01-31 0001326110 ibrx:CaMember ibrx:SecondLeaseForTheSecondFloorOfTheBuildingMember 2019-01-31 0001326110 ibrx:CaMember ibrx:FirstAndSecondLeaseMember 2019-01-31 0001326110 ibrx:DuleyRoadLlcMember ibrx:SecondLeaseForTheSecondFloorOfTheBuildingMember ibrx:CaMember 2019-01-31 0001326110 ibrx:FirstLeaseMember ibrx:DuleyRoadLlcMember 2019-01-31 0001326110 ibrx:SecondLeaseMember ibrx:DuleyRoadLlcMember 2019-01-31 0001326110 ibrx:NantcapitalMember 2019-01-31 0001326110 ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember us-gaap:SeriesBPreferredStockMember 2019-01-31 0001326110 ibrx:ImmunoOncologyClinicIncMember 2019-07-01 2019-07-31 0001326110 ibrx:ImmunoOncologyClinicIncMember srt:MaximumMember stpr:CA 2021-03-31 2021-03-31 0001326110 ibrx:ImmunoOncologyClinicIncMember 2019-10-01 2019-10-31 0001326110 stpr:CA ibrx:ImmunoOncologyClinicIncMember 2019-07-31 0001326110 ibrx:ImmunoOncologyClinicIncMember stpr:CA 2019-10-31 0001326110 ibrx:ViractaTherapeuticsIncMember srt:MinimumMember 2017-05-31 2017-05-31 0001326110 ibrx:ViractaTherapeuticsIncMember srt:MaximumMember 2017-05-31 2017-05-31 0001326110 ibrx:ViractaTherapeuticsIncMember 2017-05-31 2017-05-31 0001326110 ibrx:RushUniversityMedicalCenterLicenseAgreementMember 2004-12-31 2004-12-31 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember 2016-06-27 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember ibrx:QualifiedFinancingMember 2016-06-27 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember ibrx:InCaseOfChangeOfControlMember 2016-06-27 0001326110 ibrx:GlobeimmuneExclusiveLicenseAgreementMember 2020-01-01 2020-01-31 0001326110 ibrx:GlobeimmuneExclusiveLicenseAgreementMember ibrx:ClinicalAndRegulatoryMilestonesMember 2020-01-01 2020-01-31 0001326110 ibrx:ConvertibleNotesReceivableMember ibrx:RiptideBioscienceMember 2016-06-27 2016-06-27 0001326110 ibrx:AltorBioscienceCorporationMember ibrx:CaMember 2017-02-28 0001326110 ibrx:AltorBioscienceCorporationMember ibrx:CaMember 2017-02-01 2017-02-28 0001326110 ibrx:PrecigenLicenseAgreementMember ibrx:INDFilingMember 2010-02-28 2010-02-28 0001326110 ibrx:PrecigenLicenseAgreementMember ibrx:PhaseTwoMember 2010-02-28 2010-02-28 0001326110 ibrx:PrecigenLicenseAgreementMember ibrx:PhaseThreeMember 2010-02-28 2010-02-28 0001326110 ibrx:PrecigenLicenseAgreementMember ibrx:CommercialSaleRelatedToLicensedProductsMember 2010-02-28 2010-02-28 0001326110 ibrx:PrecigenLicenseAgreementMember 2010-02-28 2010-02-28 0001326110 ibrx:CommitmentSanDiegoMember 2015-06-30 0001326110 ibrx:CommitmentSanDiegoMember 2015-06-01 2015-06-30 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember 2015-04-10 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember ibrx:SalesMilestoneMember 2015-04-10 0001326110 ibrx:NantWorksLimitedLiabilityCompanyMember ibrx:VivaBioCellMember 2015-04-10 2015-04-10 0001326110 ibrx:ReceptomeMember 2016-10-04 0001326110 ibrx:ReceptomeMember 2016-10-04 2016-10-04 0001326110 ibrx:ReceptomeMember 2018-05-31 0001326110 ibrx:ReceptomeMember 2018-05-01 2018-05-31 0001326110 ibrx:CelgeneEntitiesMember ibrx:GlobeImmuneMember 2017-04-28 0001326110 ibrx:CelgeneEntitiesMember ibrx:GlobeImmuneMember 2017-04-28 2017-04-28 0001326110 ibrx:PrecisionBiologicsMember ibrx:InvestmentsInSeriesAPreferredStockMember 2015-10-02 0001326110 ibrx:PrecisionBiologicsMember ibrx:InvestmentsInSeriesAPreferredStockMember 2015-10-02 2015-10-02 0001326110 ibrx:PrecisionBiologicsMember ibrx:InvestmentsInSeriesAPreferredStockMember 2019-07-20 2019-07-20 0001326110 ibrx:NantcancerstemcellLlcMember ibrx:NantbioIncMember 2018-08-31 0001326110 ibrx:SorrentoMember ibrx:NantbioIncMember 2018-08-31 0001326110 ibrx:NcscMember 2018-08-31 0001326110 ibrx:TwoLeasesMember ibrx:DuleyRoadLlcMember 2019-01-01 2019-01-31 0001326110 ibrx:DuleyRoadLlcMember 2019-01-01 2019-01-31 0001326110 ibrx:NantcapitalMember 2019-01-01 2019-01-31 0001326110 ibrx:NantHealthLabsIncMember 2018-03-01 2018-03-31 0001326110 ibrx:CalcapMember 2020-10-15 0001326110 ibrx:CalcapMember 2019-03-01 2019-03-31 0001326110 ibrx:CalcapMember 2019-03-31 0001326110 ibrx:NantcapitalMember 2015-12-31 0001326110 ibrx:NantcapitalMember 2020-07-31 0001326110 ibrx:NantcapitalMember 2020-08-31 0001326110 ibrx:NantworksMember 2017-06-30 0001326110 ibrx:NantcapitalMember ibrx:SixPercentPromissoryNotesMember 2020-09-30 0001326110 us-gaap:WarrantMember 2020-12-31 0001326110 us-gaap:CommonStockMember 2020-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001326110 us-gaap:RetainedEarningsMember 2020-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001326110 us-gaap:StockholdersEquityTotalMember 2020-12-31 0001326110 us-gaap:NoncontrollingInterestMember 2020-12-31 0001326110 us-gaap:EmployeeStockOptionMember 2018-12-31 0001326110 us-gaap:CommonStockMember 2018-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001326110 us-gaap:RetainedEarningsMember 2018-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001326110 us-gaap:StockholdersEquityTotalMember 2018-12-31 0001326110 us-gaap:NoncontrollingInterestMember 2018-12-31 0001326110 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001326110 us-gaap:WarrantMember 2018-12-31 0001326110 us-gaap:WarrantMember 2019-12-31 0001326110 us-gaap:CommonStockMember 2019-12-31 0001326110 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001326110 us-gaap:RetainedEarningsMember 2019-12-31 0001326110 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001326110 us-gaap:StockholdersEquityTotalMember 2019-12-31 0001326110 us-gaap:NoncontrollingInterestMember 2019-12-31 utr:sqft iso4217:USD xbrli:pure utr:Year xbrli:shares utr:Month utr:Day iso4217:USD xbrli:shares ibrx:Employees ibrx:Security ibrx:Officer
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM
8-K/A
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 5, 2021
 
 
ImmunityBio, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
001-37507
  
43-1979754
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
3530 John Hopkins Court
San Diego
,
California
92121
(Address of principal executive offices, including zip code)
(858)
633-0300
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
 
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
  
IBRX
  
Nasdaq Global Select Market
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
 
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
 
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
Explanatory Note
As previously reported, on March 10, 2021, ImmunityBio, Inc. (formerly known as NantKwest, Inc.) (the “Company”) completed its merger with NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) (“ImmunityBio”), in accordance with the terms of the Agreement and Plan of Merger, dated December 21, 2020 (the “Merger Agreement”), by and among the Company, Nectarine Merger Sub, Inc. (“Merger Sub”), and ImmunityBio, pursuant to which Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of the Company (the “Merger”) and subsequently renamed NantCell, Inc. This Amendment No. 1 on
Form 8-K/A is
being filed by the Company to amend the Current Report on
Form 8-K filed
on March 10, 2021 (the “Original Report”), solely to provide the financial statements and pro forma financial information required by Item 9.01 of
Form 8-K that
were not previously filed with the Original Report in reliance on the instructions to such Item and to voluntarily include the related Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Capitalized terms used but not defined herein have the meanings assigned to them in the Original Report.
 
Item 8.01
Other Events
Included herewith as Exhibit 99.3 and incorporated by reference herein, is the related Management’s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio, based on the Combined Consolidated financial statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.).
 
Item 9.01
Financial Statements and Exhibits
(a) Financial Statements of Business Acquired
The financial statements required by Item 9.01(a) and the notes related thereto are filed as Exhibit 99.1 to this report.
(b) Pro Forma Financial Information
The pro forma financial information required by Item 9.01(b) and the notes related thereto are filed as Exhibit 99.2 to this report.
(d) Exhibits.
 
Exhibit
Number
   
Exhibit Title
23.1    Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm
23.2    Consent of Ernst & Young, LLP, Independent Auditors
99.1    Consolidated financial statements of NantCell, Inc. (fka ImmunityBio, Inc., a private company), as of December 31, 2020 and December 31, 2019
99.2    Combined Consolidated financial statements of ImmunityBio, Inc., as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.)
99.3    Management’s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio, Inc. (based on the Combined Consolidated financial statements of ImmunityBio, Inc., as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.))
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
IMMUNITYBIO, INC.
Date: April 22, 2021
     By:  
/s/ David Sachs
      Chief Financial Officer